We had the honor of welcoming Natalie Phelps, a young mother of two and #coloncancer advocate with the Colorectal Cancer Alliance, to speak at Arcus. Natalie spoke to her firsthand account of the extraordinary challenges that people with cancer face every day. She shared insights into how people make treatment decisions such as weighing efficacy with side effects and how the healthcare industry can make it easier for patients and caregivers to navigate finding clinical trials. Her raw, honest and at times heartbreaking journey was both moving and eye-opening, a powerful motivation to continue to think differently and strive for breakthroughs. People like Natalie are waiting. Thank you, Natalie, for sharing your story.
Arcus Biosciences
Biotechnology
Hayward, California 21,680 followers
Global, biopharmaceutical company at the forefront of designing precision combinations in the pursuit of cures
About us
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.
- Website
-
http://www.arcusbio.com
External link for Arcus Biosciences
- Industry
- Biotechnology
- Company size
- 501-1,000 employees
- Headquarters
- Hayward, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- Protein Therapeutics, Immuno-oncology, Medicinal Chemistry, and Large Molecule Drug Discovery
Locations
-
Primary
3928 Point Eden Way
Hayward, California 94545, US
-
1800 Sierra Point Pkwy
Brisbane, California 94005, US
Employees at Arcus Biosciences
-
Emily Walsh
Talent Acquisition & HR Consultant, Pharmaceutical Research, Development & Operations
-
Leslie Mesones Miller
Talent & Leadership Development | Team Effectiveness | Executive Coaching | HR Business Partnership – Understands and leverages individual and team…
-
Eric Matthews
Chief Commercial Officer, Arcus Biosciences
-
Matt Donnelly
Supply Chain and Operations Management Executive | Building and Leading High Performing Organizations
Updates
-
Last week we presented clinical findings at #KCRS24 on our investigational small molecule HIF-2α inhibitor being developed in #kidneycancer. It’s always inspiring to join such a dedicated community of clinicians, researchers and scientists working together to make a meaningful difference for those living with this disease. Thank you for having us KidneyCAN! Access our poster here: https://bit.ly/3WmLBzq
-
This afternoon, our CMO Dimitry Nuyten will be presenting at KidneyCAN’s #KCRS24 Biotech Showcase where he’ll provide an overview of Arcus’s research in #kidneycancer, including our small molecule HIF-2α inhibitor. We look forward to an opportunity to discuss emerging therapeutics being developed for kidney cancer and collaborate with fellow clinical and translational researchers driving these advancements. Learn more about our science here: https://bit.ly/3S6i0tA
-
When Terry was first diagnosed with #lungcancer, her doctors didn’t think she'd survive more than three months. She faced many difficulties, traversing the road independently, but found her own light along the way and is proud of who she has become: her own advocate and a mentor to support others. View Terry's portrait and the rest of the digital gallery at AIPortraitsOfCancer.com #PortrAItsofCancer LUNGevity Foundation
-
We have published new preclinical research for AB598, an investigational therapeutic antibody designed to inhibit CD39 enzymatic activity for immuno-oncology. Read more about our latest findings on AB598 here: https://bit.ly/3WmLBzq
-
We are pleased to announce that Taiho Pharmaceutical Co., Ltd., exercised its options for an exclusive license to another Arcus program. We look forward to this collaboration and the ongoing partnership in Japan and other territories in Asia. Read more: https://bit.ly/3VYtn85
-
As #CancerImmunotherapyMonth comes to a close, we remain committed to discovering new approaches to cancer immunotherapy that open the door to potential novel treatments for patients in need. At Arcus, we have focused on building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio. Learn from our President Juan Jaen and CMO Dimitry Nuyten about how we are targeting the #adenosineaxis to harness the body’s own immune system to attack and destroy #coloncancer: https://bit.ly/3VbWzJg
-
We are honored to share that Arcus has been recognized as one of Fortune's 2024 Best Workplaces (small and medium, across industries) in the Bay Area™. At Arcus, we have invested in a strong foundation of smart people and good science, working every day to bring life-changing new therapies to people with cancer. See what makes us a great place to work: https://bit.ly/3VEtSoS #BestWorkplaces, #GPTWcertified
-
Tomorrow morning, our CEO Terry Rosen and COO Jennifer Jarrett will participate in a fireside chat hosted by Salveen Richter at the Goldman Sachs 45th Annual Global Healthcare Conference. You can watch a livestream of the chat here: https://bit.ly/4bVJNEW
-
We are pleased to announce the completion of patient enrollment for STAR-221, a Phase 3 study evaluating a domvanalimab-containing regimen in patients with metastatic upper GI cancers. Read more about the announcement here: https://bit.ly/3xcqfgs